Liraglutide Lawsuit: NY Claims & Legal Options

Liraglutide (sold as Victoza and Saxenda) has been linked to gastroparesis (stomach paralysis), ileus and intestinal blockage, gallbladder disease, and in some reports, vision loss (NAION). Earlier litigation also raised concerns about acute pancreatitis and thyroid tumors, including medullary thyroid carcinoma, which remains a black-box warning on the label, though a causal link in humans has not been scientifically established. Plaintiffs allege manufacturers failed to adequately warn patients and prescribing physicians about these risks despite internal safety data.

Yes. New York residents harmed by liraglutide can pursue product liability claims against manufacturers like Novo Nordisk under theories of failure to warn, defective design, or negligence. Current litigation is consolidated in a federal MDL (In re: GLP-1 Receptor Agonists Products Liability Litigation) centered on gastrointestinal injuries. Under CPLR §214, you generally have three years from the date of injury; under CPLR §214-c, New York's discovery rule for latent injuries from exposure to a substance, that clock can instead start from when you reasonably discovered the injury and its connection to liraglutide — so consult an attorney even if the exposure happened years ago.

Victims may seek damages for medical expenses, lost wages, pain and suffering, and long-term disability. New York does not cap compensatory damages in personal injury cases, so recoverable amounts depend on the severity of harm, the strength of evidence, and the specific facts of each case. No outcome is guaranteed.

Preserve all medical records, prescription history, and documentation of your diagnosis. Contact a NY personal injury attorney as soon as possible — the 3-year SOL under CPLR §214 begins running from the date of injury or discovery. An attorney can evaluate whether your case qualifies for individual litigation or joinder in a mass tort proceeding.